EP2097061A2 - Utilisation de styphnolobium - Google Patents

Utilisation de styphnolobium

Info

Publication number
EP2097061A2
EP2097061A2 EP07847462A EP07847462A EP2097061A2 EP 2097061 A2 EP2097061 A2 EP 2097061A2 EP 07847462 A EP07847462 A EP 07847462A EP 07847462 A EP07847462 A EP 07847462A EP 2097061 A2 EP2097061 A2 EP 2097061A2
Authority
EP
European Patent Office
Prior art keywords
hair
acid
use according
styphnolobium
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07847462A
Other languages
German (de)
English (en)
Inventor
Thomas Welss
Melanie Giesen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of EP2097061A2 publication Critical patent/EP2097061A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Definitions

  • the present invention relates to the use of an agent containing active ingredients obtainable from plants of the genus Styphnolobium for the treatment of hair.
  • Hair growth is not a continuous process, but occurs in growth and hair loss bouts that repeat cyclically. This process is essentially due to the fact that hair follicle cells are subject to a genetically determined cycle of growth, regression and resting phase. The hair follicle is thus the only organ that constantly renews itself and thus exhibits a unique metabolism, depending on the respective growth phase. Thus, the hair follicle metabolism almost completely stops in the resting phase and is also reinitiated with each new beginning of another cycle. This cycle is controlled by a small, highly specialized cell population in the hair bulb, the dermal papilla cells, which controls hair growth through a unique complex system of molecular signals specific to each phase of the hair cycle.
  • the genus Styphnolobium (Schnurbäume) has as subspecies Styphnolobium affine (Sophora affinis), Styphnolobium japonicum (Sophora japonica) and Styphnolobium montevirdis on.
  • the Japanese cord tree originally came from China and then spread to East Asia (Japan, Korea).
  • Styphnolobium montevirdis is native to Central America and Styphnolobium affine in South America (Texas, Oklahoma, Arkansas, Louisiana).
  • the Japanese scrape tree contains rutin (also known as vitamin P), which is used in the pharmaceutical industry for medications and in the healing of the blood circulation, are prescribed for nerve diseases and inflammation.
  • agents containing active substances from plants of the genus Styphnolobium are suitable for stimulating the release of growth factors and fortifying the hair by stimulating the proliferation of the hair keratinocytes.
  • the present invention therefore relates to the use of an agent containing active compounds which are obtainable from plants of the genus Styphnolobium for the treatment of hair, in particular for stimulating hair growth, reducing hair loss and strengthening hair.
  • Styphnolobium is in particular selected from the group consisting of Styphnolobium affine (Sophora affinis), Styphnolobium japonicum (Sophora japonica), Styphnolobium montevirdis, with Styphnolobium japonicum (Sophora japonica) being particularly preferred.
  • the active ingredients are obtained from the Styphnolobium plant as extracts.
  • the extracts of the said plant are usually provided by extraction with water, organic solvents, such as liquid hydrocarbons at room temperature, ethers or alcohols, and mixtures thereof.
  • Preferred extractants are water and / or alcohols.
  • the alcohols are (C 1 to C 6 ) - alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol, propylene glycol and butylene glycol both as sole extractant and in admixture with water, preferred.
  • Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.
  • a Sophora Japonica flower extract from Symrise is used.
  • This extract is extracted from the flowers of the tree. After purification and drying, an aqueous extract is obtained by maceration and percolation. The filtrate is subsequently concentrated by distillation and gently spray-dried. To produce 0.15 kg of extract, 1 kg of dried flowers are used.
  • a further advantage of the present invention is that the application of said agents positively influences hair structure, growth and metabolism by stimulating hair-specific structural proteins (hair keratins).
  • hair keratins hair-specific structural proteins
  • the active substances of the Styphnolobium plant are preferably obtained from the leaves, flowers, stems, roots, tubers and / or seeds, with very particular preference they are obtained from the flowers.
  • the flower extract of Sophora japonica is used.
  • the proportion of the active substances from the Styphnolobium plant in the agents used according to the invention is preferably 0.00001 to 5 wt .-%, preferably 0.0001 to 2.5 wt .-%, particularly preferably 0.001 to 1 wt .-% in the overall composition ,
  • the agents used according to the invention may further contain auxiliaries and additives which are usually added to the respective cosmetic agents.
  • the agents used according to the invention may contain, for example, additional constituents selected from the group comprising protein hydrolysates, film-forming substances, further hair growth stimulating active ingredients, nonionic surfactants, anionic surfactants, zwitterionic surfactants, ampholytic surfactants, nonionic polymers, care substances, Thickeners, perfume oils, dyes, light stabilizers, antioxidants, antidandruff agents, propellants, reducing agents.
  • agents used according to the invention may contain a cationic surfactant selected from quaternary ammonium compounds, esterquats and amidoamines.
  • compositions used according to the invention are preferably shampoos, hair conditioners, hair lotions, hair gels, hair conditioners, hair cream, hair lotions, hair sprays or hair tinctures.
  • the agents can of course be rinsed out, but preferably they should remain on the hair.
  • the agent can be rinsed off after a contact time.
  • This rinsing can be done with pure water or a commercially available shampoo.
  • Haartonics especially as a leave on formulation. These are preferably used at room temperature, the alcoholic content is preferably in the range of about 30% to about 35% and the pH should be about pH 7.
  • a silicone oil and / or a silicone gum can be used as a care material.
  • the agents contain at least one silicone oil and / or a silicone gum.
  • Silicone oils or silicone gums which are suitable according to the invention are, in particular, dialkyl- and alkylarylsiloxanes, for example dimethylpolysiloxane and methylphenylpolysiloxane, and also their alkoxylated, quaternized or else anionic derivatives. Preference is given to cyclic and linear polydialkylsiloxanes, their alkoxylated and / or aminated derivatives, dihydroxypolydimethylsiloxanes and polyphenylalkylsiloxanes.
  • the agent preferably contains a silicone derivative as a conditioner
  • the agent contains, instead of or in addition to a silicone component, at least one conditioner of a different class of compounds.
  • the agents may contain, for example, at least one protein hydrolyzate and / or one of its derivatives.
  • Protein hydrolysates are product mixtures obtained by acid, alkaline or enzymatically catalyzed degradation of proteins (proteins).
  • the term protein hydrolyzates also means total hydrolyzates as well as individual amino acids and their derivatives as well as mixtures of different amino acids.
  • polymers made up of amino acids and amino acid derivatives are understood by the term protein hydrolyzates. The latter include, for example, polyalanine, polyasparagine, polyserine, etc.
  • Further examples of compounds which can be used according to the invention are L-alanyl-L-proline, polyglycine, glycyl-L-glutamine or D / L-methionine-S-methylsulfonium chloride.
  • ⁇ -amino acids and their derivatives such as ⁇ -alanine, anthranilic acid or hippuric acid can also be used.
  • the molecular weight of the protein hydrolysates which can be used according to the invention is between 75, the molecular weight for glycine, and 200,000, preferably the molecular weight is 75 to 50,000 and very particularly preferably 75 to 20,000 daltons.
  • protein hydrolysates of both vegetable and animal or marine or synthetic origin can be used.
  • Animal protein hydrolysates are, for example, elastin, collagen, keratin, silk and milk protein hydrolysates, which may also be present in the form of salts.
  • Such products are, for example, under the trademarks Dehylan ® (Cognis), Promois® ® (Interorgana) Collapuron ® (Cognis), Nutrilan® ® (Cognis), Gelita-Sol ® (German Gelatinefabriken Stoess & Co), Lexein ® (Inolex) sericin (Pentapharm) and kerasol tm ® (Croda) sold.
  • silk protein hydrolysates By silk one understands the fibers of the cocoon of the mulberry silkworm (Bombyx mori L.).
  • the raw silk fiber consists of a double thread fibroin.
  • sericin holds this double thread together.
  • Silk consists of 70-80% by weight of fibroin, 19-28% by weight of sericin, 0.5-1% by weight of fat and 0.5-1% by weight of dyes and mineral constituents.
  • the essential components of sericin are with about 46 wt .-% Hydroxyamino acids.
  • the sericin consists of a group of 5 to 6 proteins.
  • the essential amino acids of the sericin are serine (Ser, 37% by weight), aspartate (Asp, 26% by weight), glycine (Gly, 17% by weight), alanine (Ala), leucine (Leu) and tyrosine (Tyr).
  • the water-insoluble fibroin belongs to the skieroproteins with a long-chain molecular structure.
  • the main components of the fibroin are glycine (44% by weight), alanine (26% by weight), and tyrosine (13 Wt .-%).
  • Another essential structural feature of the fibroin is the hexapeptide sequence SerGIy-AIa-GIy-AIa-Gly.
  • compositions according to the invention Preference is therefore given in the compositions according to the invention as a silk protein hydrolyzate an active substance complex (A) consisting of the active substance (A1) selected from sericin, sericin hydrolysates and / or derivatives thereof, and mixtures thereof, and an active ingredient (A2) selected from fibroin, and / or fibroin hydrolysates and / or derivatives thereof and / or mixtures thereof.
  • A1 selected from sericin, sericin hydrolysates and / or derivatives thereof, and mixtures thereof
  • active ingredient (A2) selected from fibroin, and / or fibroin hydrolysates and / or derivatives thereof and / or mixtures thereof.
  • the active ingredient complex (A) significantly synergistically improves the above-described essential internal and external structural features and the strength and elasticity of human hair.
  • active ingredients (A1) it is possible to use in the active ingredient complex (A): native sericin, hydrolyzed and / or further derivatized sericin, such as commercial products with the INCI names Sericin, Hydrolyzed Sericin, or Hydrolyzed SiIk, a mixture of the amino acids serine, aspartate and glycine and / or their methyl, propyl, iso-propyl, butyl, iso-butyl esters, their salts such as hydrochlorides, sulfates, acetates, citrates, tartrates, in which mixture the serine and / or its Derivatives to 20 to 60 wt.%, The aspartate and / or its derivatives to 10 - 40 wt.% And the glycine and / or its derivatives to 5 to 30 wt.% Are included, with the proviso that the amounts of these Amino acids and / or their derivatives preferably add to 100 wt.%, And
  • active ingredients (A2) can be used in the active ingredient complex (A): native, converted into a soluble form fibroin, hydrolyzed and / or further derivatized fibroin, particularly partially hydrolyzed fibroin, which contains as its main component the amino acid sequence Ser-Gly-Ala-Gly-Ala Gly, the amino acid sequence Ser-Gly-Ala-Gly-Ala-Gly, a mixture of the amino acids glycine, alanine and tyrosine and / or their methyl, propyl, iso-propyl, butyl, iso-butyl esters, their salts such as hydrochlorides, sulfates, acetates, citrates, tartrates, wherein in this mixture, the glycine and / or its derivatives in amounts of 20- 60 wt.%, The alanine and its derivatives in amounts of 10 - 40 wt%, and the tyrosine and its derivatives are contained in amounts of
  • Particularly good nourishing properties can be achieved if one of the two active ingredient components of the active ingredient complex (A) is used in the native or at most solubilized form. It is also possible to use a mixture of several active substances (A1) and / or (A2).
  • the two active compounds (A1) and (A2) in the ratio of 10:90 to 70:30, in particular 15:85 to 50:50 and very particularly 20:80 to 40:60, based on their respective Contents of active substance in the agents used in the invention can be used.
  • the derivatives of sericin and fibroin hydrolysates include both anionic and cationized protein hydrolysates.
  • the protein hydrolyzates of sericin and fibroin and the derivatives prepared therefrom can be obtained from the corresponding proteins by chemical, in particular alkaline or acid hydrolysis, by enzymatic hydrolysis and / or a combination of both types of hydrolysis.
  • the hydrolysis of proteins usually results in a protein hydrolyzate having a molecular weight distribution of about 100 daltons up to several thousand daltons. Preference is given to those protein hydrolysates of sericin and fibroin and / or derivatives thereof, whose underlying protein content has a molecular weight of 100 to 25,000 daltons, preferably 250 to 10,000 daltons.
  • cationic protein hydrolysates of sericin and fibroin are also quaternized amino acids and mixtures thereof to understand.
  • the quaternization of the protein hydrolysates or amino acids is often carried out using quaternary ammonium salts such as N, N-dimethyl-N- (n-alkyl) -N- (2-hydroxy-3-chloro-n-propyl) ammonium halides.
  • the cationic protein hydrolysates may also be further derivatized.
  • cationic protein hydrolyzates and derivatives which can be used according to the invention, those mentioned under the INCI names in the "International Cosmetic Ingredient Dictionary and Handbook", (seventh edition 1997, The Cosmetic, Toiletry, and Fragrance Association 1 101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) and commercially available products: Cocodimonium Hydroxypropyl Hydrolyzed SiCl, Cocodimonium Hydroxypropyl SiIk Amino Acids, Hydroxyproypltrimonium Hydrolyzed Silica, Lauryldimonium Hydroxypropyl Hydrolyzed Silica, Steardimonium Hydroxypropyl Hydrolyzed Silica, Quaternium 79 Hydrolyzed Silica.
  • anionic protein hydrolysates and derivatives those listed under the INCI names in the "International Cosmetic Ingredient Dictionary and Handbook", (seventh edition 1997, The Cosmetic, Toiletry, and Fragrance Association 1 101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) and commercially available products: Potassium Cocoyl Hydrolyzed SiIk, Sodium Lauroyl Hydrolyzed SiIk or Sodium Stearoyl Hydrolyzed SiIk.
  • Palmitoyl Oligopeptide Palmitoyl Pentapeptide-3, Palmitoyl Pentapeptide-2, Acetyl Hexapeptide-1, Acetyl Hexapeptide-3, Copper Tripeptide-1, Hexapeptide-1 , Hexapeptide-2, MEA-Hydrolyzed SiIk.
  • the effect of the active ingredient complex (A) can be further increased by the addition of fatty substances.
  • Fatty substances are to be understood as meaning fatty acids, fatty alcohols, natural and synthetic waxes, which may be in solid form as well as liquid in aqueous dispersion, and natural and synthetic cosmetic oil components.
  • Protein hydrolysates of vegetable origin eg. As soybean, almond, pea, potato and wheat protein hydrolysates are, for example, under the trademarks Gluadin ® (Cognis), DiaMin ® (Diamalt), Lexein ® (Inolex), Hydrosoy ® (Croda), Hydrolupin ® (Croda) , hydro Sesame ® (Croda), Hydro tritium ® (Croda) and Crotein ® (Croda) available.
  • protein hydrolysates Although the use of the protein hydrolysates is preferred as such, amino acid mixtures otherwise obtained may be used in their place, if appropriate. Also possible is the use of derivatives of protein hydrolysates, for example in the form of their fatty acid condensation products. Such products are, for example, among the Designations Lamepon® ® (Cognis), Lexein ® (Inolex), Crolastin ® (Croda), Crosilk (Croda) or crotein ® (Croda) sold.
  • the protein hydrolysates are present in the agents used according to the invention, for example in concentrations of from 0.01% by weight to 20% by weight, preferably from 0.05% by weight to 15% by weight and most preferably in amounts of 0.05 wt .-% up to 5 wt .-%, each based on the total application preparation included.
  • some nourishing polymers can also have film-forming and / or setting properties, and can therefore also be used as film-forming and / or setting polymers.
  • a first group of caring polymers are the cationic polymers.
  • Cationic polymers are to be understood as meaning polymers which have a group in the main and / or side chain which may be “temporary” or “permanent” cationic.
  • “permanently cationic” refers to those polymers which have a cationic group, irrespective of the pH of the agent. These are usually polymers containing a quaternary nitrogen atom, for example in the form of an ammonium group.
  • Preferred cationic groups are quaternary ammonium groups.
  • those polymers in which the quaternary ammonium group are bonded via a CI_ 4 hydrocarbon group to a synthesized from acrylic acid, methacrylic acid or derivatives thereof, polymer backbone have been found to be particularly suitable.
  • R 1 -H or -CH 3
  • R 2, R 3 and R 4 are independently selected from CI_ 4 -alkyl, -alkenyl or -hydroxyalkyl groups
  • m 1, 2, 3 or 4
  • n a natural number
  • X ' is a physiologically acceptable organic or inorganic anion, as well as copolymers consisting essentially of the monomer units listed in formula (G 1-1) and nonionic monomer units, are particularly preferred cationic polymers.
  • R 1 is a methyl group
  • R 2 , R 3 and R 4 are methyl groups m has the value 2.
  • Suitable physiologically tolerable counterions X " include, for example, halide ions, sulfate ions, phosphate ions, methosulfate ions and organic ions such as lactate, citrate, tartrate and acetate ions, preference being given to halide ions, in particular chloride.
  • a particularly suitable homopolymer is, if desired, crosslinked, poly (meth acryloyloxyethyltrimethylammonium chloride) with the INCI name Polyquaternium-37.
  • the crosslinking can be carried out with the aid of poly olefinically unsaturated compounds, for example divinylbenzene, tetraallyloxyethane, methylenebisacrylamide, diallyl ether, polyallylpolyglyceryl ethers, or allyl ethers of sugars or sugar derivatives such as erythritol, pentaerythritol, arabitol, mannitol, sorbitol, sucrose or glucose.
  • Methylenebisacrylamide is a preferred crosslinking agent.
  • the homopolymer is preferably used in the form of a non-aqueous polymer dispersion which should not have a polymer content of less than 30% by weight.
  • Such polymer dispersions are (under the names Salcare ® SC 95 about 50% polymer content, additional components: mineral oil (INCI name: Mineral Oil) and tridecyl-polyoxypropylene-polyoxyethylene-ether (INCI name: PPG-1 trideceth-6) ) and Salcare ® SC 96 (about 50% polymer content, additional components: mixture of diesters of propylene glycol (with a mixture of caprylic and capric acid INCI name: propylene glycol Dicaprylate / Dicaprate) and tridecyl polyoxypropylene-polyoxyethylene-ether (INCI name: PPG-1-Trideceth-6)) commercially available.
  • Copolymers with monomer units of the formula (G1-I) contain, as nonionic monomer units, preferably acrylamide, methacrylamide, acrylic acid C-. 4- alkyl esters and methacrylic acid C
  • the acrylamide is particularly preferred.
  • These copolymers can also be crosslinked, as described above in the case of the homopolymers.
  • a copolymer preferred according to the invention is the crosslinked acrylamide-methacryloyloxyethyltrimethylammonium chloride copolymer.
  • Such copolymers in which the monomers are present in a weight ratio of about 20:80, are commercially available as approximately 50% non-aqueous polymer dispersion 92 under the name Salcare ® SC.
  • cationic polymers are, for example quaternized cellulose derivatives, such as are available under the names of Celquat ® and Polymer JR ® commercially.
  • the compounds Celquat ® H 100, Celquat ® L 200 and Polymer JR ® 400 are preferred quaternized cellulose derivatives, cationic alkyl polyglycosides, cationized honey, for example the commercial product Honeyquat ® 50, cationic guar derivatives, in particular under the trade name Cosmedia ® guar and Jaguar ® distributed products,
  • Quaternary group polysiloxanes such as the commercially available products Q2-7224 (manufactured by Dow Corning, a stabilized trimethylsilylamodimethicone), Dow Corning® 929 emulsion (containing a hydroxylamino-modified silicone, also referred to as amodimethicones), SM -2059 (manufacturer: General Electric), SLM-55067 (manufacturer: Wacker) and Abil ® -Quat 3270 and 3272 (manufacturer: Th Goldschmidt.), diquaternary polydimethylsiloxanes, quaternium-80), polymeric dimethyldiallylammonium salts and their copolymers with esters and amides of acrylic acid and methacrylic acid.
  • Q2-7224 manufactured by Dow Corning, a stabilized trimethylsilylamodimethicone
  • Dow Corning® 929 emulsion containing a hydroxylamino-modified silicone, also referred
  • Such compounds are sold under the names Gafquat ® 734 and Gafquat ® 755 commercially,
  • Vinylpyrrolidone-vinyl imidazolium copolymers such as those offered under the names Luviquat ® FC 370, FC 550, FC 905 and HM 552, quaternized polyvinyl alcohol, as well as by the names of Polyquaternium 2, Polyquaternium 17, Polyquaternium 18 and Polyquaternium 27, having quaternary Nitrogen atoms in the polymer backbone.
  • Can be used as cationic polymers are sold under the names Polyquaternium-24 (commercial product z. B. Quatrisoft ® LM 200), known polymers.
  • copolymers of vinylpyrrolidone such as the commercial products Copolymer 845 (manufactured by ISP), Gaffix ® VC 713 (manufactured by ISP), Gafquat ® ASCP 101 1, Gafquat ® HS 110, Luviquat ® 8155 and Luviquat ® MS 370 are available.
  • cationic polymers which can be used according to the invention are the so-called "temporary cationic" polymers. These polymers usually contain an amino group which, at certain pH values, is present as quaternary ammonium group and thus cationic. Preferred are for example, chitosan and its derivatives, as they are freely available commercially, for example, under the trade names Hydagen ® CMF, Hydagen ® HCMF, Kytamer ® PC and Chitolam ® NB / 101.
  • cationic polymers are cationic cellulose derivatives and chitosan and its derivatives, in particular the commercial products Polymer ® JR 400, Hydagen ® HCMF and Kytamer ® PC, cationic guar derivatives, cationic honey derivatives, in particular the commercial product Honeyquat ® 50, cationic Alkyl polyglycodides and Polyquaternium-37 type polymers.
  • cationized protein hydrolysates are to be counted among the cationic polymers, wherein the underlying protein hydrolyzate from the animal, for example from collagen, milk or keratin, from the plant, for example from wheat, corn, rice, potatoes, soy or almonds, marine life forms, for example from fish collagen or algae, or biotechnologically derived protein hydrolysates.
  • the protein hydrolyzates on which the cationic derivatives according to the invention are based can be obtained from the corresponding proteins by chemical, in particular alkaline or acid hydrolysis, by enzymatic hydrolysis and / or a combination of both types of hydrolysis.
  • cationic protein hydrolyzates are to be understood as meaning quaternized amino acids and mixtures thereof.
  • the quaternization of the protein hydrolyzates or amino acids is often carried out using quaternary ammonium salts such as N, N-dimethyl-N- (n-alkyl) -N- (2-hydroxy-3-chloro-n-propyl) ammonium halides.
  • the cationic protein hydrolysates may also be further derivatized.
  • the cationic protein hydrolysates and derivatives according to the invention those mentioned under the INCI names in the "International Cosmetic Ingredient Dictionary and Handbook", (seventh edition 1997, The Cosmetic, Toiletry and Fragrance Association 1 101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) and commercially available products called: Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Hydroxypropyl Arginine Lauryl / My
  • amphoteric polymers are those polymers which are composed essentially
  • R 1 -CH CR 2 -CO-Z- (C n H 2n ) -N (+) R 3 R 4 R 5 A () (II) in R 1 and R 2 independently represent hydrogen or a methyl group and R 3 , R 4 and R 5 each independently represent an alkyl group having 1 to 4 carbon atoms, Z represents an NH group or an oxygen atom, n represents an integer of 2 to 5 and A is the anion of an organic or inorganic acid, and
  • These compounds can be used both directly and in salt form, which is obtained by neutralization of the polymers, for example with an alkali metal hydroxide, according to the invention.
  • Very particular preference is given to those polymers in which monomers of the type (a) are used in which R 3 , R 4 and R 5 are methyl groups, Z is an NH group and A () is a halide, methoxysulfate or ethoxysulfate ion is; Acrylamidopropyltrimethylammonium chloride is a particularly preferred monomer (a).
  • Acrylic acid is preferably used as monomer (b) for the stated polymers.
  • the agents used according to the invention preferably contain the caring, cationic and / or amphoteric polymers in an amount of from 0.01 to 5% by weight, in particular in an amount of from 0.1 to 2% by weight, based in each case on entire application preparation.
  • the agents used according to the invention contain further hair growth stimulating agents.
  • Suitable hair growth stimulating agents for example, minoxidil (6-piperidino-2,4-pyrimidinediamine-3-oxide), aminexil (diaminopyrimidine oxide), finasteride (N-tert-butyl-3-oxo-4-aza-5 ⁇ -androst- 1-en-17ß-carboxamide), carnitine tartrate and 5- ⁇ -reductase inhibitors.
  • a 5- ⁇ reductase inhibitors are particularly suitable for the functional C 2 -C 2 carboxylic acids and their physiologically acceptable metal salts, in particular 10-hydroxydecanoic acid, 10-hydroxydecenic acid and its derivatives, derivatives of C 3 -C 9 polyols, phenol derivatives, plant extracts, Fragrances, flavonoids, isoflavonoids, 6,7-disubstituted 2,2-dialkylchromans or chromenes, aluminum chlorohydrate, 2-phenylethanol, etidronic acid, 7-acetyl-1,1,1,4,4,4,6-hexamethyltetralin, tropolone derivatives, Esters of sulfuric acid with alkoxylated C 8 -C 18 -fatty alcohols and their physiologically acceptable metal salts, esters of phosphoric acid and triphosphoric acid with monovalent to hexavalent hydroxy compounds, silicic acid esters, isolable from marine organisms mycosporin-like amino acids (MAA) and quaternary
  • the agents used according to the invention may furthermore contain at least one vitamin, one provitamin, one vitamin precursor and / or one of their derivatives.
  • vitamins, provitamins and vitamin precursors are preferred, which are usually assigned to groups A, B, C, E, F and H.
  • vitamin A includes retinol (vitamin A 1 ) and 3,4-didehydroretinol (vitamin A 2 ).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the agents preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total application preparation.
  • the vitamin B group or the vitamin B complex include vitamin B 1 (thiamine) vitamin B 2 (riboflavin) Vitamin B 3 .
  • Vitamin B 1 thiamine
  • vitamin B 2 riboflavin
  • Vitamin B 3 the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • Preferred according to the invention is the nicotinic acid amide, which is preferably present in the agents used according to the invention in amounts of from 0.05 to 1% by weight, based on the total application preparation.
  • Vitamin B 5 pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group.
  • panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols.
  • Individual representatives are, for example, panthenol triacetate, panthenol monoethyl ether and its monoacetate, as well as cationic panthenol derivatives.
  • the said compounds of the vitamin B 5 type are contained in the agents used according to the invention preferably in amounts of 0.05-10% by weight, based on the total application preparation. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin B 6 (pyridoxine and pyridoxamine and pyridoxal).
  • the said compounds of the vitamin B 6 type are preferably contained in the agents used according to the invention in amounts of 0.01-5% by weight, based on the total application preparation. Levels of 0.05-1 wt% are particularly preferred.
  • Vitamin C (ascorbic acid). Vitamin C is used in the compositions according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total application preparation. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the compositions according to the invention in amounts of 0.05-1% by weight, based on the total application preparation ,
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-c /] -imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed.
  • Biotin is contained in the agents used according to the invention preferably in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight, in each case based on the total application preparation.
  • the agents used according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, C, E and H. Panthenol, pantolactone, pyridoxine and its derivatives as well as nicotinic acid amide and biotin are particularly preferred.
  • the agents used according to the invention may further contain at least one plant extract.
  • extracts are produced by extraction of the whole plant. However, in individual cases it may also be preferred to prepare the extracts exclusively from flowers and / or leaves of the plant.
  • extracts of green tea, almond, aloe vera, coconut, mango, apricot, lime, wheat, kiwi and melon are especially suitable.
  • alcohols and mixtures thereof can be used as extraction agent for the preparation of said plant extracts water.
  • the alcohols are lower alcohols such as ethanol and isopropanol, but especially polyhydric alcohols such as ethylene glycol and propylene glycol, both as sole extractant and in admixture with water, are preferred.
  • Plant extracts based on water / propylene glycol in a ratio of 1:10 to 10: 1 have proven to be particularly suitable.
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in dilute form, they usually contain about 2 to 90 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.
  • compositions used according to the invention may contain a number of carboxylic acids as a care substance.
  • short-chain carboxylic acids may in particular be advantageous.
  • Short-chain carboxylic acids and their derivatives in the context of the invention are understood to mean carboxylic acids which may be saturated or unsaturated and / or straight-chain or branched or cyclic and / or aromatic and / or heterocyclic and have a molecular weight of less than 750.
  • preference may be given to saturated or unsaturated straight-chain or branched carboxylic acids having a chain length of from 1 to 16 C atoms in the chain, very particular preference being given to those having a chain length of from 1 to 12 C atoms in the chain.
  • the short-chain carboxylic acids according to the invention may have one, two, three or more carboxy groups.
  • carboxylic acids having a plurality of carboxy groups in particular di- and tricarboxylic acids.
  • the carboxy groups may be wholly or partly present as esters, acid anhydride, lactone, amide, imidic acid, lactam, lactim, dicarboximide, carbohydrazide, hydrazone, hydroxam, hydroxime, amidine, amidoxime, nitrile, phosphonic or phosphate ester.
  • the carboxylic acids which can be used according to the invention may of course be substituted along the carbon chain or the ring skeleton.
  • the substituents of the carboxylic acids which can be used according to the invention include, for example, C 1 -C 8 -alkyl, C 2 -C 8 -alkenyl, aryl, aralkyl and aralkenyl, hydroxymethyl, C 2 -C 8 -hydroxyalkyl, C 2 - Cs-hydroxyalkenyl, aminomethyl, C 2 -C 8 -aminoalkyl, cyano, formyl, oxo, thioxo, hydroxy, mercapto, amino, carboxy or imino groups.
  • Preferred substituents are C 1 -C 8 -alkyl, hydroxymethyl, hydroxy, amino and carboxy groups.
  • substituents in the ⁇ position are hydroxyl, alkoxy and amino groups, where the amino function may optionally be further substituted by alkyl, aryl, aralkyl and / or alkenyl radicals.
  • preferred carboxylic acid derivatives are the phosphonic and phosphate esters.
  • carboxylic acids which can be used according to the invention include formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, oxalic acid, malonic acid, succinic acid, glutaric acid, glyceric acid, glyoxylic acid, adipic acid, Pimelic, suberic, azelaic, sebacic, propiolic, crotonic, isocrotonic, elaidic, maleic, fumaric, muconic, citraconic, mesaconic, camphoric, benzoic, o, m, p-phthalic, naphthoic, toluoic, hydratropic, atropic, cinnamic acid, isonicotinic acid, nicotinic acid, Bicarbaminklare, 4,4 '-Dicyano-6,6' - binicotinklare, 8-
  • n is a number from 4 to 12 and one of the two groups X and Y is a COOH group and the other is hydrogen or a methyl or Ethyl radical
  • dicarboxylic acids of the general formula (NI) which additionally carry 1 to 3 methyl or ethyl substituents on the cyclohexene ring and dicarboxylic acids formed formally from the dicarboxylic acids according to formula (NI) by addition of a molecule of water to the double bond in the cyclohexene ring.
  • Dicarboxylic acids of the formula (N-I) are known in the literature.
  • US-A 3,753,968 discloses a manufacturing process.
  • the dicarboxylic acids of the formula (N-I) can be prepared, for example, by reacting polyunsaturated dicarboxylic acids with unsaturated monocarboxylic acids in the form of a Diels-Alder cyclization.
  • a polyunsaturated fatty acid as the dicarboxylic acid component.
  • Preferred is the linoleic acid obtainable from natural fats and oils.
  • the monocarboxylic acid component in particular, acrylic acid, but also e.g. Methacrylic acid and crotonic acid are preferred.
  • isomer mixtures in which one component is present in excess are formed. These isomer mixtures can be used according to the invention as well as the pure compounds.
  • those dicarboxylic acids which differ from the compounds according to formula (NI) by 1 to 3 methyl or ethyl substituents on the cyclohexyl ring or from these compounds can also be used according to the invention Formally be formed by addition of one molecule of water to the double bond of the cyclohexene ring.
  • the dicarboxylic acid (mixture), which is obtained by reacting linoleic acid with acrylic acid, has proved to be particularly effective according to the invention. It is a mixture of 5- and 6-carboxy-4-hexyl-2-cyclohexene-1-octanoic acid.
  • Such compounds are commercially available under the designations Westvaco Diacid 1550 Westvaco Diacid ® ® 1595 (manufacturer: Westvaco).
  • salts are the alkali metal salts, alkaline earth metal salts, zinc salts and ammonium salts, which in the context of the present application also includes the mono-, di- and trimethyl-, -ethyl- and -hydroxyethyl ammonium salts.
  • neutralized acids can very particularly preferably be used with alkaline-reacting amino acids, such as, for example, arginine, lysine, ornithine and histidine.
  • 2-pyrrolidinone-5-carboxylic acid and derivatives thereof as the carboxylic acid.
  • Particularly preferred are the sodium, potassium, calcium, magnesium or ammonium salts, in which the ammonium ion in addition to hydrogen carries one to three C 1 - to C 4 - alkyl groups.
  • the sodium salt is most preferred.
  • the amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total application preparation, particularly preferably from 0.1 to 5% by weight, and particularly preferably from 0.1 to 3% by weight.
  • hydroxycarboxylic acids and here again in particular the dihydroxy, trihydroxy and polyhydroxycarboxylic acids as well as the dihydroxy, trihydroxy and polyhydroxy di-, tri- and polycarboxylic acids. It has been found that, in addition to the hydroxycarboxylic acids, the hydroxycarboxylic acid esters and the mixtures of hydroxycarboxylic acids and their esters as well as polymeric hydroxycarboxylic acids and their esters can be very particularly preferred.
  • Preferred hydroxycarboxylic acid esters are, for example, full esters of glycolic acid, lactic acid, malic acid, tartaric acid or citric acid.
  • hydroxycarboxylic esters are esters of .beta.-hydroxypropionic acid, tartronic acid, D-gluconic acid, sugar acid, mucic acid or glucuronic acid.
  • Suitable alcohol components of these esters are primary, linear or branched aliphatic alcohols having 8-22 C atoms, ie, for example, fatty alcohols or synthetic fatty alcohols.
  • the esters of Ci 2 -Ci 5 fatty alcohols are particularly preferred. Esters of this type are commercially available, eg under the trademark Cosmacol® ® EniChem, Augusta Industriale.
  • Particularly preferred polyhydroxypolycarboxylic acids are polylactic acid and polyuric acid and their esters.
  • agents used according to the invention may contain oil bodies as a care substance.
  • the natural and synthetic cosmetic oil bodies include, for example: vegetable oils.
  • vegetable oils examples include sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil.
  • triglyceride oils such as the liquid portions of beef tallow as well as synthetic triglyceride oils.
  • the compounds are available as commercial products 1, 3-di- (2-ethyl-hexyl) -cyclohexane (Cetiol ® S), and di-n-octyl ether (Cetiol ® OE) may be preferred.
  • Ester oils are to be understood as meaning the esters of C 6 - C 30 fatty acids with C 2 - C 30 fatty alcohols.
  • the monoesters of the fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • Examples of fatty acid components used in the esters are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic Behenic acid and erucic acid and their technical mixtures which are obtained, for example, in the pressure splitting of natural fats and oils, in the oxidation of aldehydes from Roelen's oxo synthesis or the dimerization of unsaturated fatty acids.
  • fatty alcohol components in the ester oils are isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, Gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassidyl alcohol and their technical mixtures, for example, in the high-pressure hydrogenation of technical methyl esters based on fats and oils or aldehydes from the Roelen oxo synthesis and as a monomer fraction in the dimerization of unsaturated fatty alcohols incurred.
  • isopropyl myristate IPM Rilanit ®
  • isononanoic acid C16-18 alkyl ester Cetiol ® SN
  • 2-ethylhexyl palmitate Cegesoft ® 24
  • stearic acid-2-ethylhexyl ester Cetiol ® 868
  • cetyl oleate glycerol tricaprylate, Kokosfettalkohol- caprate / caprylate (Cetiol ® LC)
  • n-butyl stearate oleyl erucate
  • isopropyl palmitate IPP Rilanit ®
  • oleyl Oleate Cetiol ®
  • hexyl laurate Cetiol ® A
  • di-n-butyl adipate Cetiol ® B
  • myrist IPM Rilanit ®
  • Dicarboxylic acid esters such as di-n-butyl adipate, di- (2-ethylhexyl) adipate, di- (2-ethylhexyl) succinate and di-isotridecyl acelate
  • diol esters such as ethylene glycol dioleate, ethylene glycol diisotridecanoate, propylene glycol di (2- ethylhexanoate), propylene glycol diisostearate, propylene glycol di-pelargonat, butanediol di-isostearate, Neopentylglykoldicaprylat, symmetrical, asymmetrical or cyclic esters of carbonic acid with fatty alcohols, for example described in DE-OS 197 56 454, glycerol carbonate or dicaprylylcarbonate (Cetiol ® CC),
  • Fatty acid partial glycerides which are understood to mean monoglycerides, diglycerides and their technical mixtures. With the use of technical products production reasons may still contain small amounts of triglycerides.
  • the partial glycerides preferably follow the formula (D4-I),
  • R 1 , R 2 and R 3 independently of one another represent hydrogen or a linear or branched, saturated and / or unsaturated acyl radical having 6 to 22, preferably 12 to 18, carbon atoms, with the proviso that at least one of these groups represents a Acyl radical and at least one of these groups is hydrogen.
  • the sum (m + n + q) is 0 or numbers from 1 to 100, preferably 0 or 5 to 25.
  • R 1 is an acyl radical and R 2 and R 3 are hydrogen and the sum (m + n + q) is 0.
  • Typical examples are mono- and / or diglycerides based on caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic , Elaeostearic acid, arachidic acid, gadoleic acid, behenic acid and erucic acid and their technical mixtures.
  • oleic acid monoglycerides are used.
  • the amount used of the natural and synthetic cosmetic oil bodies in the compositions according to the invention is usually from 0.1 to 30% by weight, based on the total application preparation, preferably from 0.1 to 20% by weight, and in particular from 0.1 to 15% by weight. %.
  • the agent may further contain an enzyme as a conditioner.
  • enzymes according to the invention are selected from a group which is formed from proteases, lipases, transglutaminase, oxidases and peroxidases.
  • it may be necessary for them to further comprise at least one surfactant. This is especially true for shampoos. But also other agents, such as hair conditioners, hair treatments, hair tonic, hair cream, hair lotions, hair tinctures.
  • compositions may further contain cationic surfactants selected from quaternary ammonium compounds, esterquats and amidoamines.
  • Preferred quaternary ammonium compounds are ammonium halides, especially chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides, e.g. Cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride, as well as the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
  • the long alkyl chains of the above-mentioned surfactants preferably have 10 to 18 carbon atoms.
  • Esterquats are known substances which contain both at least one ester function and at least one quaternary ammonium group as a structural element.
  • Preferred esterquats are quaternized ester salts of fatty acids with triethanolamine, quaternized ester salts of fatty acids with diethanolalkylamines and quaternized ester salts of fatty acids with 1,2-dihydroxypropyldialkylamines.
  • Such products are sold, for example, under the trademarks Stepantex®, Dehyquart® and Armocare®.
  • alkylamidoamines are usually prepared by amidation of natural or synthetic fatty acids and fatty acid cuts with dialkylaminoamines.
  • a particularly suitable compound according to the invention from this group of substances is stearamidopropyl-dimethylamine, which is commercially available under the name Tegoamid® S 18.
  • the cationic surfactants are contained in the compositions according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total application preparation. Amounts of 0.1 to 5 wt .-% are particularly preferred.
  • the agents may contain other surfactants or emulsifiers, with both anionic and ampholytic and nonionic surfactants and all types of known emulsifiers being suitable in principle.
  • the group of ampholytic or amphoteric surfactants includes zwitterionic surfactants and ampholytes.
  • the surfactants may already have emulsifying effect.
  • a combination of anionic and nonionic surfactants or a combination of anionic and amphoteric surfactants is used.
  • the skilled person can also largely or completely dispense with the use of surfactants.
  • Suitable anionic surfactants are in principle all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule.
  • anionic surfactants are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group, linear and branched fatty acids having 8 to 30 C atoms (Soap),
  • Ethercarbon Acid the formula RO- (CH2 "CH2 ⁇ ) ⁇ -CH2-COOH, in which R is a linear
  • Alkyl group having 8 to 30 C atoms and x 0 or 1 to 16,
  • Alpha sulfo fatty acid methyl esters of fatty acids having 8 to 30 carbon atoms, - alkyl sulfates and alkyl polyglycol ether sulfates of the formula RO (CH 2 -CH 2 O) x -OSO 3 H, in which R is a preferably linear alkyl group having 8 to 30 carbon atoms and x 0 or 1 to 12,
  • esters of tartaric acid and citric acid with alcohols the addition products of about 2-15
  • R 1 is preferably an aliphatic hydrocarbon radical having 8 to 30 carbon atoms
  • R 2 is hydrogen, a radical (CH 2 CH 2 O) n R 1 or X, n is from 1 to 10 and X is hydrogen Alkali or alkaline earth metal or NR 3 R 4 R 5 R 6 , where R 3 to R 6 independently of one another represent hydrogen or a C 1 to C 4 hydrocarbon radical, is a sulfated fatty acid alkylene glycol ester of the formula (E1-II)
  • R 7 CO- for a linear or branched, aliphatic, saturated and / or unsaturated acyl radical having 6 to 22 carbon atoms, Alk for CH 2 CH 2 , CHCH 3 CH 2 and / or CH 2 CHCH 3 , n for numbers from 0.5 to 5 and M is a cation, as described in DE-OS 197 36 906, monoglyceride sulfates and monoglyceride ether sulfates of the formula (E1-III)
  • R 8 CO is a linear or branched acyl radical having 6 to 22 carbon atoms
  • x, y and z are in total 0 or numbers of 1 to 30, preferably 2 to 10
  • X is an alkali or alkaline earth metal.
  • monoglyceride (ether) sulfates suitable for the purposes of the invention are the reaction products of lauric acid monoglyceride, coconut fatty acid monoglyceride, palmitic acid monoglyceride, stearic acid monoglyceride, oleic acid monoglyceride and tallow fatty acid monoglyceride and their ethylene oxide adducts with sulfur trioxide or chlorosulfonic acid in the form of their sodium salts.
  • monoglyceride sulfates of the formula (E1-III) are used in which R 8 CO is a linear acyl radical having 8 to 18 carbon atoms, amide-ether carboxylic acids,
  • Condensation products of C 8 - C 30 - fatty alcohols with protein hydrolysates and / or amino acids and their derivatives which are known to the skilled person as protein fatty acid condensates, such as Lamepon ® - types Gluadin ® - types Hostapon ® KCG or Amisoft ® - types.
  • Preferred anionic surfactants are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic acid monoalkylpolyoxyethylester with 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups, Monoglycerdisulfate, alkyl and Alkenyletherphosphate and Eiweissfettkladensate.
  • Zwitterionic surfactants are those surface-active compounds which carry at least one quaternary ammonium group and at least one -COO () or -SO 3 () group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyl dimethylammonium glycinate, N-acylaminopropyl N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3-carboxymethyl-3-hydroxyethyl-imidazolines having in each case 8 to 18 C atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate.
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name
  • Ampholytes are understood as meaning those surface-active compounds which, apart from a C 8 -C 24 -alkyl or -acyl group in the molecule, contain at least one free amino group and at least one -COOH or -SO 3 H group and are capable of forming internal salts.
  • ampholytes are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group.
  • Particularly preferred ampholytes are N-cocoalkylaminopropionate, cocoacylaminoethyl aminopropionate and C 2 - C 8 - sarcosine.
  • Nonionic surfactants contain as hydrophilic group e.g. a polyol group, a polyalkylene glycol ether group, or a combination of polyol and polyglycol ether groups.
  • hydrophilic group e.g. a polyol group, a polyalkylene glycol ether group, or a combination of polyol and polyglycol ether groups.
  • Such compounds are, for example
  • alkylphenols having 8 to 15 carbon atoms in the alkyl group such as those available under the trade names Dehydol ® LS, LT Dehydol ® types (Cognis), C 2 -C 3 o-Fett Acidnono- and diesters of addition products of 1 to 30 mol ethylene oxide onto glycerol,
  • Polyol fatty acid esters such as the commercial product Hydagen ® HSP (Cognis) or
  • R 1 CO for a linear or branched, saturated and / or unsaturated acyl radical having 6 to 22 carbon atoms
  • R 2 is hydrogen or methyl
  • R 3 is linear or branched
  • R 4 is an alkyl or alkenyl radical having 4 to 22 carbon atoms
  • G is a sugar radical having 5 or 6 carbon atoms
  • p is a number from 1 to 10. They can be obtained by the relevant methods of preparative organic chemistry.
  • the alkyl and alkenyl oligoglycosides can be derived from aldoses or ketoses with 5 or 6 carbon atoms, preferably glucose.
  • the preferred alkyl and / or alkenyl oligoglycosides are thus alkyl and / or alkenyl oligoglucosides.
  • the index number p in the general formula (E4-II) indicates the degree of oligomerization (DP), ie the distribution of mono- and oligoglycosides and stands for a number between 1 and 10.
  • the value p for a given alkyloligoglycoside is an analytically determined arithmetic quantity, which usually represents a fractional number. Preference is given to using alkyl and / or alkenyl oligoglycosides having an average degree of oligomerization p of from 1.1 to 3.0. From an application point of view, those alkyl and / or alkenyl oligoglycosides are preferred whose degree of oligomerization is less than 1.7, and in particular between 1, 2 and 1, 4 lies.
  • the alkyl or alkenyl radical R 4 can be derived from primary alcohols having 4 to 11, preferably 8 to 10 carbon atoms. Typical examples are butanol, caproic alcohol, caprylic alcohol, capric alcohol and undecyl alcohol and technical mixtures thereof, as obtained, for example, in the hydrogenation of technical fatty acid methyl esters or in the hydrogenation of aldehydes from Roelen's oxo synthesis.
  • the alkyl or alkenyl radical R 15 can also be derived from primary alcohols having 12 to 22, preferably 12 to 14 carbon atoms.
  • Typical examples are lauryl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol, brassidyl alcohol, and technical mixtures thereof which can be obtained as described above.
  • R 5 is CO for an aliphatic acyl radical having 6 to 22 carbon atoms
  • R 6 is hydrogen, an alkyl or hydroxyalkyl radical having 1 to 4 carbon atoms
  • [Z] is a linear or branched polyhydroxyalkyl radical having 3 to 12 carbon atoms and 3 to 10 hydroxyl groups stands.
  • the fatty acid N-alkyl polyhydroxyalkylamides are known substances which can usually be obtained by reductive amination of a reducing sugar with ammonia, an alkylamine or an alkanolamine and subsequent acylation with a fatty acid, a fatty acid alkyl ester or a fatty acid chloride.
  • the fatty acid N-alkylpolyhydroxyalkylamides are derived from reducing sugars having 5 or 6 carbon atoms, especially glucose.
  • the preferred fatty acid N-alkylpolyhydroxyalkylamides are therefore fatty acid N-alkylglucamides as represented by the formula (E4-IV):
  • the fatty acid N-alkylpolyhydroxyalkylamides used are preferably glucamides of the formula (E4-IV) in which R 8 is hydrogen or an alkyl group and R 7 is CO for the acyl radical of caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, Palmoleinklare, stearic acid, isostearic acid, oleic acid, elaidic acid, petroselinic acid, linoleic acid, linolenic acid, arachidic acid, gadoleic acid, behenic acid or erucic acid or technical mixtures of these acids.
  • R 8 is hydrogen or an alkyl group
  • R 7 is CO for the acyl radical of caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, Palmoleinklare, stearic acid, isostearic acid, oleic acid, e
  • fatty acid N-alkylglucamides of the formula (E4-IV) which are obtained by reductive amination of glucose with methylamine and subsequent acylation with lauric acid or C 12/14 coconut fatty acid or a corresponding derivative.
  • the polyhydroxyalkylamides can also be derived from maltose and palatinose.
  • the preferred nonionic surfactants are the alkylene oxide addition products of saturated linear fatty alcohols and fatty acids having in each case 2 to 30 moles of ethylene oxide per mole of fatty alcohol or fatty acid. Preparations having excellent properties are also obtained if they contain fatty acid esters of ethoxylated glycerol as nonionic surfactants.
  • the alkyl radical R contains 6 to 22 carbon atoms and may be both linear and branched. Preference is given to primary linear and methyl-branched in the 2-position aliphatic radicals.
  • Such alkyl radicals are, for example, 1-octyl, 1-decyl, 1-lauryl, 1-myristyl, 1-cetyl and 1-stearyl. Particularly preferred are 1-octyl, 1-decyl, 1-lauryl, 1-myristyl.
  • oxo-alcohols compounds with an odd number of carbon atoms in the alkyl chain predominate.
  • sugar surfactants may be present as nonionic surfactants. These are preferably present in amounts of 0.1 to 20 wt .-%, based on the respective total composition. Amounts of 0.5 to 15 wt .-% are particularly preferred, and very particularly preferred amounts of from 0.5 to 7.5 wt .-%.
  • the compounds used as surfactant with alkyl groups may each be uniform substances. However, it is generally preferred to use native vegetable or animal raw materials in the production of these substances, so that substance mixtures having different alkyl chain lengths depending on the respective raw material are obtained.
  • both products with a "normal” homolog distribution and those with a narrow homolog distribution can be used.
  • "normal” homolog distribution are meant mixtures of homologs obtained in the reaction of fatty alcohol and alkylene oxide using alkali metals, alkali metal hydroxides or alkali metal alcoholates as catalysts. Narrowed homolog distributions are obtained when, for example Hydrotalcites, alkaline earth metal salts of ether carboxylic acids, alkaline earth metal oxides, hydroxides or - alkoxides can be used as catalysts.
  • the use of products with narrow homolog distribution may be preferred.
  • the other surfactants are generally in amounts of 0.1 to 45 wt .-%, preferably 0.5 to 30 wt .-% and most preferably from 0.5 to 25 wt .-%, based on the respective total Composition, used.
  • the amount used depends essentially on the purpose of the agent used in the invention. If it is a shampoo or other cleansing agent, surfactant levels above 45% by weight are also common.
  • the agents furthermore contain at least one emulsifier and / or at least one dialkyl ether.
  • Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion.
  • Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O emulsions. The selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion.
  • Emulsifiers which can be used according to the invention are, for example
  • Glucosides mixtures of alkyl (oligo) and fatty alcohols for example, the commercially available product ® Montanov 68,
  • Sterols are understood to mean a group of steroids which carry a hydroxyl group on C-atom 3 of the steroid skeleton and are isolated both from animal tissue (zoosterines) and from vegetable fats (phytosterols). Examples of zoosterols are Cholesterol and lanosterol. Examples of suitable phytosterols are ergosterol,
  • glucose phospholipids e.g. as lecithins or phosphatidylcholines from e.g. Egg yolk or plant seeds (e.g., soybeans) are understood.
  • Fatty acid esters of sugars and sugar alcohols such as sorbitol
  • Polyglycerols and polyglycerol derivatives such as polyglycerol poly-12-hydroxystearate
  • the emulsifiers are preferably used in amounts of 0.1 to 25 wt .-%, in particular 0.1 to 3 wt .-%, based on the respective total composition.
  • Emulsifiers which are particularly suitable according to the invention are polyethylene glycol alkyl ethers having alkyl chain lengths of 6 to 30 carbon atoms, preferably 12 to 22 carbon atoms and a degree of ethoxylation of 1 to 1000, preferably 1 to 500 and in particular 1 to 100.
  • Particularly preferred polyethylene glycol ethers for the purposes of the invention are the substances known by the INCI name ceteareth-6, ceteareth-9, ceteareth-10, ceteareth-20, ceteareth-30, ceteareth-25, steareth-10 and steareth-20.
  • emulsifiers in the context of the invention are C 12 -C 22 -fatty acid mono- and diesters of addition products of 1 to 30 moles of ethylene oxide onto polyols having 3 to 6 carbon atoms, in particular glycerol.
  • Particularly suitable are PEG-20 glyceryl stearates, PEG-7 glyceryl cocoate, PEG-30 glyceryl stearate, PEG-6 caprylic / capric glycerides, polyglyceryl-3-diisostearate and glycereth-2-cocoate.
  • Nonionic emulsifiers having an HLB value of 8 to 18, according to the methods described in the Römpp Lexikon Chemie (Hrg. J. Falbe, M. Regitz), 10th edition, Georg Thieme Verlag Stuttgart, New York, (1997), page 1764, listed definitions.
  • Nonionic emulsifiers with an HLB value of 10 to 16 are particularly preferred according to the invention.
  • suitable dialkyl ethers are di-n-alkyl ethers containing a total of 5 to 50 carbon atoms, preferably 8 and 40 and especially with 12 to 24 carbon atoms, such as di-n-octyl ether (Cetiol ® OE), di-n decyl ether, di-n-nonyl ether, di-n-undecyl ether, di-n-dodecyl ether, n-hexyl-n-octyl ether, n-octyl-n-decyl ether, n-decyl-n-undecyl ether, n-undecyl-n- dodecyl ether and n-hexyl n-undecyl ether and di-tert-butyl ether, di-iso-pentyl ether, di-3-ethyl decyl ether, tert-
  • Particularly suitable according to the invention is dicaprylyl ether.
  • the agents used according to the invention contain the dialkyl ethers preferably in amounts of 0.01-50 wt .-%, preferably in amounts of 0.05 to 20 wt .-% and in particular in amounts of 0.1 to 15 wt .-%, based on the entire remedy.
  • agents may also contain at least one thickening agent. This is especially true when the agent is a gel or a paste.
  • Suitable thickening agents are, for example, agar-agar, guar gum, alginates, xanthan gum, gum arabic, karaya gum, locust bean gum, linseed gums, dextrans, celulose derivatives, e.g. As methylcellulose, hydroxyalkylcellulose and carboxymethylcellulose, starch fractions and derivatives such as amylose, amylopectin and dextrins, clays such. Bentonite, fully synthetic hydrocolloids such as e.g. Polyvinyl alcohol, and optionally crosslinked polyacrylates.
  • the polymers which have been described as possible care substances or are listed below as film-forming and / or setting polymers may have thickening properties and may optionally be used as thickeners.
  • the agents may furthermore contain all active ingredients, additives and auxiliaries known for corresponding cosmetic agents. These are for example
  • Structurants such as maleic acid and lactic acid
  • Solvents and mediators such as ethanol, isopropanol, ethylene glycol, propylene glycol, glycerol and diethylene glycol, quaternized amines such as methyl-1-alkylamidoethyl-2-alkylimidazolinium methosulfate
  • Anti-dandruff agents such as Piroctone Olamine, Zinc Omadine and Climbazole,
  • Bodying agents such as sugar esters, polyol esters or polyol alkyl ethers,
  • Fats and waxes such as spermaceti, beeswax, montan wax and paraffins,
  • Swelling and penetration substances such as glycerol, propylene glycol monoethyl ether, carbonates,
  • Hydrogencarbonates such as latex, styrene / PVP and styrene / acrylamide copolymers
  • Pearlescing agents such as ethylene glycol mono- and distearate and PEG-3-distearate,
  • Propellants such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 and air,
  • compositions can be carried out in all forms customary for cosmetic products, for example in the form of solutions which can be applied to the hair as hair lotions or pump or aerosol spray, in the form of emulsions, waxes, gels or surfactant-containing foaming solutions or others Preparations suitable for use on the hair.
  • the agents used according to the invention are hair treatment agents, in particular shampoo, hair conditioner, hair tonic, hair gel, hair tonic, hair conditioner, hair cream, hair lotion, hair spray and hair tincture.
  • the agents can be used, for example, as creams, lotions, solutions, waters, emulsions such as W / O, O / W, PIT emulsions (called phase inversion emulsions, PIT), microemulsions and multiple emulsions, gels, sprays, aerosols and formulated foam aerosols.
  • emulsions such as W / O, O / W, PIT emulsions (called phase inversion emulsions, PIT), microemulsions and multiple emulsions, gels, sprays, aerosols and formulated foam aerosols.
  • the funds can be made up as a single-chamber system or as a two-chamber system.
  • the product is an aerosol product, it necessarily contains a propellant.
  • Propellants suitable according to the invention are, for example, N 2 O, dimethyl ether, CO 2, air and alkanes having 3 to 5 carbon atoms, such as propane, n-butane, isobutane, n-pentane and isopentane, and mixtures thereof. Preference is given to dimethyl ether, propane, n-butane, isobutane and mixtures thereof.
  • the alkanes mentioned, mixtures of said alkanes or mixtures of said alkanes with dimethyl ether are used as the sole blowing agent.
  • the invention expressly also includes the concomitant use of propellants of the type of chlorofluorocarbons, but in particular of fluorocarbons.
  • the sizes of the aerosol droplets or of the foam bubbles and the respective size distribution can be set for a given spraying device.
  • blowing agent used varies depending on the specific composition of the composition, the packaging used and the desired product type, such as hair spray or hair foam.
  • aerosol foam products contain the propellant preferably in amounts of 1 to 35 wt .-%, based on the total product. Amounts of 2 to 30 wt .-%, in particular from 3 to 15 wt .-% are particularly preferred. Aerosol sprays generally contain larger amounts of propellant.
  • the blowing agent is used in this case in an amount of 30 to 98 wt .-%, based on the total product. Amounts of 40 to 95 wt .-%, in particular from 50 to 95 wt .-% are particularly preferred.
  • the aerosol products can be prepared in the usual way.
  • all constituents of the respective agent with the exception of the propellant, are introduced into a suitable pressure-resistant container. This is then closed with a valve.
  • the desired amount of blowing agent is introduced.
  • the agents may also be other hair treatment agents, e.g. Hair dye and corrugating agent, act. These agents then optionally contain the known substantive dyes, precursors for oxidation dyes (developer and coupler components) and oxidizing or reducing agents.
  • the agents can thus protect the hair from the stress of dyeing, activate the hair follicle and at the same time reduce or relieve skin irritation through the hair or hair dye.
  • Another object of the invention is the use of the means for revitalizing hair, activation of hair follicles, promotion or enhancement of hair growth, hair conditioning, to reduce hair loss and / or to treat hair loss.
  • Another object of the present invention is a cosmetic method for revitalizing hair, activation of hair follicles, promoting or enhancing hair growth, hair conditioning, to reduce hair loss and / or for the treatment of hair loss, wherein the compositions used in the invention on the hair, scalp Hairy skin or on skin areas where hair growth has been discontinued for a long time, but where hair growth is desired, is applied.
  • Example 1 Determination of Cell Vitality of Cultured Fibroblasts After Treatment with Sophora Japonica Flower Extract
  • the determination of the vitality of cultured cells provides information about the metabolic status of the cells
  • the vitality of cultured cells is determined by redox dyes. These dyes penetrate into the cell and are absorbed by electrons at the outer mitochondrial
  • Membrane reduced. This reduction requires a dye change, which is determined photometrically below.
  • the untreated control is set equal to 100% and the
  • the determination of the proliferation of cultured cells provides information about the status of the cell division of the treated cells. With this analysis, both cell division stimulating and inhibiting substances can be defined. An outstanding feature during cell division is the doubling of the DNA. During the new synthesis, nucleotides are incorporated into the newly formed DNA strand. The proliferation can be measured by offering a non-natural nucleotide derivative (Bromo deoxy uridine, BrdU) to the cells for re-synthesis, which can subsequently be detected with specific antibodies. The amount of newly synthesized DNA can now be quantified fluorimetrically and provides proportional information about the extent of cell division processes.
  • a non-natural nucleotide derivative Bromo deoxy uridine, BrdU
  • the untreated control is set equal to 100% and the measurements of the substance-treated samples are referenced thereto.
  • a relative proliferation of less than 80% is called inhibitory, with greater than or equal to 120% of stimulating substance effects.
  • Hepatocyte Growth Factor HGF
  • Keratinocyte Growth Factor KGF
  • HGF Hepatocyte Growth Factor
  • KGF Keratinocyte Growth Factor
  • the differential gene expression was determined by means of quantitative RT-PCR (reverse transcription polymerase chain reaction). After culturing the dermal papilla cells, they were incubated for 24 h with Sophora Japonica flower extract in the concentration of 0.1 and 0.01%.
  • the RNA is first isolated from the dermal papilla cells using the RNeasy Mini Kit from Qiagen and transcribed into cDNA by means of reverse transcription.
  • the subsequent PCR reaction which is carried out with the aid of gene-specific primers for the respective hair-relevant genes and which serves to amplify the gene sections sought, the formation of the PCR products is detected online via a fluorescence signal.
  • the fluorescence signal is proportional to the amount of the PCR product formed. The stronger the expression of a particular gene, the greater the amount of PCR product produced and the higher the fluorescence signal.
  • the untreated control is set equal to 1 and the expression of the genes to be determined referred to (x-fold expression). Values greater than or equal to twice the expression or less than or equal to 0.5 times the expression of the untreated control are classified as significantly differentially expressed. Values that greater than or equal to 1.6X expression or less than or equal to 0.66X expression of the untreated control are considered to tend to be differentially expressed.
  • Example 4 Detection of growth factor release using organotypic hair follicle cell cultures
  • the growth factor Hepatocyte Growth Factor is an important regulator of hair growth. In a potentially growth-promoting and the hair-strengthening substance can be expected to increase the factors released into the medium.
  • the release of HGF can be quantified using commercially available ELISA kits. For this purpose, organotypic hair follicle cell cultures were incubated for 72 h with Sophora Japonica flower extract and the concentration of the growth factor in the medium was quantified in the manner described.
  • Table 4 Increase in HGF release in [%] after treatment of organotypic hair follicle cell cultures compared to untreated controls.
  • HGF plays a key role in the regulation of the hair cycle. A high concentration in the hair follicle is detected in the phase of active hair growth (Anagen). Further studies showed that in addition to the activation of hair follicle growth HGF leads to a significant delay in the regression phase of hair follicles (catagen). This in turn leads to a significant extension of the hair growth phase and a reduction in hair loss. In addition, HGF controls cell proliferation in the hair matrix. Increased proliferation can thicken the hair matrix and potentially affect the volume of the hair fiber.
  • the hair structure is essentially dependent on the composition of specific hair-specific structural proteins, the hair keratins. By influencing the composition of these specific proteins, it is possible to influence the hair structure on a biological level.
  • the expression of various hair keratins in the organotypic models can be examined by means of a quantitative real-time PCR method.
  • the RNA is first isolated from the organotypic models using the RNeasy Mini Kit from Qiagen and transcribed into cDNA by means of reverse transcription.
  • the subsequent PCR reaction which is carried out with the aid of gene-specific primers for the respective hair keratins and which serves to amplify the desired gene segments, the formation of the PCR products is detected online via a fluorescence signal.
  • the fluorescence signal is proportional to the amount of the PCR product formed. The stronger the expression of a particular gene, the greater the amount of PCR product produced and the higher the fluorescence signal.
  • the untreated control is set equal to 1 and the expression of the genes to be determined referred to (x-fold expression). Values greater than or equal to 1.8 times the expression of the untreated control are classified as significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'utilisation d'un agent contenant des principes actifs qui peuvent être obtenus à partir de plantes du genre Styphnolobium pour le traitement des cheveux, en particulier pour stimuler la croissance capillaire, minimiser la chute des cheveux et renforcer le cheveu. Les principes actifs sont de préférence extraits des feuilles, des fleurs, des tiges, des racines, des bulbes et/ou des graines de la plante Styphnolobium, plus préférentiellement des fleurs.
EP07847462A 2006-12-13 2007-11-28 Utilisation de styphnolobium Ceased EP2097061A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006059270A DE102006059270A1 (de) 2006-12-13 2006-12-13 Verwendung von Styphnolobium
PCT/EP2007/062939 WO2008071546A2 (fr) 2006-12-13 2007-11-28 Utilisation de styphnolobium

Publications (1)

Publication Number Publication Date
EP2097061A2 true EP2097061A2 (fr) 2009-09-09

Family

ID=39099891

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07847462A Ceased EP2097061A2 (fr) 2006-12-13 2007-11-28 Utilisation de styphnolobium

Country Status (3)

Country Link
EP (1) EP2097061A2 (fr)
DE (1) DE102006059270A1 (fr)
WO (1) WO2008071546A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102659715B1 (ko) * 2021-07-06 2024-05-10 (주)젠셀 천연 성분을 포함하는 발모 촉진용 화장료 조성물 및 이의 제조 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517321A (ja) * 1991-07-12 1993-01-26 Goro Kawaguchi 養毛剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU83173A1 (fr) * 1981-02-27 1981-06-05 Oreal Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion
US5171573A (en) * 1989-09-28 1992-12-15 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo 4G -alpha-D-glucopyranosyl rutin, and its preparation and uses
JP2926432B2 (ja) * 1990-06-11 1999-07-28 株式会社林原生物化学研究所 養毛剤
CN1040618C (zh) * 1993-09-13 1998-11-11 马菱 生发精及其制备方法
CN1040503C (zh) * 1994-07-02 1998-11-04 重庆奥妮化妆品有限公司(中外合资) 含营养去屑止痒中药添加剂的洗发剂
DE29522372U1 (de) * 1994-12-13 2002-11-21 Beiersdorf Ag, 20253 Hamburg Kosmetische und dermatologische Zubereitungen mit Flavonoiden
JPH10218737A (ja) * 1997-02-10 1998-08-18 Taisho Pharmaceut Co Ltd 育毛剤
JP4488560B2 (ja) * 1999-10-26 2010-06-23 一丸ファルコス株式会社 保湿性植物抽出物を含有する化粧料組成物
EP1129686B1 (fr) * 2000-01-31 2005-07-06 Shiseido Company Limited Produits de nettoyage
JP2002193753A (ja) * 2000-12-27 2002-07-10 Shiseido Co Ltd 養毛剤
JP2004137227A (ja) * 2002-10-21 2004-05-13 Lion Corp エアゾール化粧料
KR100514132B1 (ko) * 2003-06-13 2005-09-09 한호숙 체중 감소용 생약 조성물 및 이를 포함하는 체중 감소용 키트
DE102006053344A1 (de) * 2006-11-10 2008-05-15 Henkel Kgaa Haarbehandlung zur Verringerung der Haarschädigung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517321A (ja) * 1991-07-12 1993-01-26 Goro Kawaguchi 養毛剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199309, Derwent World Patents Index; Class B05, AN 1993-071001, "Tonic for promoting hair growth - comprises vitamin-P containing eriodictin and vitamin-C for imparting elasticity to scalp capillaries" *

Also Published As

Publication number Publication date
WO2008071546A3 (fr) 2009-07-23
WO2008071546A2 (fr) 2008-06-19
DE102006059270A1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
EP2054020B1 (fr) Agent cosmétique contenant de la purine et/ou un dérivé de purine et de la taurine
EP1594448B1 (fr) Agents de traitement capillaire avec des melanges de tensioactifs
EP1812117B1 (fr) Procede de restructuration de fibres keratiniques
EP1927378A1 (fr) Agent de traitement capillaire comprenant de la quercetine et son utilisation pour revitaliser les cheveux
DE102015222976A1 (de) Haarpflegemittel enthaltend Caseinhydrolysat zur Verbesserung der Haarstruktur
EP1690524B1 (fr) Dérivés de cellulose cationique dans des compositions cosmétiques
EP1404286B1 (fr) Agent de soin capillaire comprenant un tartrate de carnitine
EP2248509A2 (fr) Champoings doux pour les cheveux et le cuir chevelu et conditionneur
WO2008043644A2 (fr) Utilisation d'extrait de pissenlit pour épaissir les cheveux et stimuler la pousse des cheveux
EP2272499B1 (fr) Produits de coiffage apportant une tenue forte en atmosphère humide
DE102004024509B4 (de) Verfahren und Zubereitungen zur Restrukturierung von Haaren
DE19823552A1 (de) Zubereitung zur Behandlung der menschlichen Haut und der menschlichen Haare mit einer speziellen Wirkstoffkombination sowie Verwendung dieser Wirkstoffkombination
DE102011089366A1 (de) Haarwuchsmittel enthaltend Moringa Extrakt
DE102007013143A1 (de) Verwendung von Purin und Purinderivate zur Haarbehandlung
EP2097061A2 (fr) Utilisation de styphnolobium
DE102004045253A1 (de) Kationische Copolymere und ihre Verwendung in haarkosmetischen Zubereitungen
EP2489345B1 (fr) Produits de coiffage apportant une tenue forte en atmosphère humide III
EP1363586B1 (fr) Procede de mise en forme durable de fibres keratinique et produit correspondant
WO2008031685A1 (fr) Extrait de racine issu de harpagophytum pour stimuler la pousse des cheveux
DE102013210463A1 (de) Haarwuchsmittel enthaltend Leontopodium Extrakt
DE10258394A1 (de) Tücher zur Pflege keratinischer Fasern
EP2061425A1 (fr) Extrait de apium graveolens pour stimuler la pousse des cheveux
EP1569605B1 (fr) Etoffes de nettoyage pour nettoyer des fibres de keratine
DE102009028085A1 (de) Verwendung von Olivenöl und Proteinhydrolysaten in der Haarpflege
EP2238966A2 (fr) Shampooings doux et conditionneur pour le cuir chevelu

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090615

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20100809

R17C First examination report despatched (corrected)

Effective date: 20100526

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120311